Clinical trials: HIV Infections, completed
Toxoplasmosis, Cerebral, HIV Infections
A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine
To evaluate the safety and tolerance of atovaquone (566C80) in AIDS patients with central nervous system (CNS) toxoplasmosis. To evaluate the efficacy of 566C80 in the acute treatment and suppression of CNS toxoplasmosis in AIDS…
- Trial name
- NCT00001994
- Testing
- Atovaquone
- Where
- 22 sites in United States, Canada
- Sponsor
- Glaxo Wellcome
Hepatitis, Hepatitis C
An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients
The purpose of the study is to demonstrate the noninferiority of Algeron in combination with ribavirin compared to PegIntron in combination with ribavirin in treatment of chronic hepatitis C in Human Immunodeficiency Virus-1…
- Conditions
- Hepatitis, Hepatitis C, Hepatitis C/ Human Immunodeficiency Virus Coinfection
- Trial name
- NCT02103439
- Testing
- Algeron, PegIntron
- Where
- 6 sites in Russia
- Volunteers
- 140 people
- Sponsor
- Biocad
HIV Infections
ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla
A single tablet regimen (STR) of efavirenz, emtricitabine and tenofovir disoproxil fumarate (tenofovir DF) is the first complete HAART that is offered as one tablet once a day.
- Trial name
- ONCE (NCT00615745)
- Testing
- Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg
- Where
- United Kingdom
- Volunteers
- 115 people
- Sponsor
- Gilead Sciences
HIV Infections
Evaluating Immune Function Tests in People With HIV
Some people's immune systems are able to control HIV infection without anti-HIV drugs. Other people with HIV must take drugs to prevent the virus from destroying their immune systems.
- Trial name
- NCT00067795
- Where
- 6 sites in United States
- Volunteers
- 54 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation
Human immunodeficiency virus (HIV)-1 infected participants receiving long-term therapy with lamivudine or emtricitabine (nucleoside reverse transcriptase inhibitors [NRTIs]) are at risk for the development of a mutation at…
- Trial name
- Resistance (NCT00312039)
- Testing
- Elvucitabine, Lamivudine
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Tuberculosis
A Study of MVA85A in Healthy Infants
This was a Phase II double-blinded randomized controlled evaluation of safety, immunogenicity and efficacy of MVA85A/AERAS-485 in Bacillus Calmette-Guérin (BCG) vaccinated infants without tuberculosis or HIV infection.
- Trial name
- NCT00953927
- Testing
- MVA85A/AERAS-485, Candida Skin Test Antigen
- Where
- 3 sites in South Africa
- Volunteers
- 2,797 people, healthy volunteers welcome
- Sponsor
- Aeras
HIV Infection
Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers
The development of a safe and effective HIV-1 vaccine strategy would probably be the best solution for the ultimate control of the worldwide AIDS pandemic.
- Trial name
- VRI01 (NCT02038842)
- Testing
- LIPO-5, MVA HIV-B (MVATG17401), GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots
- Where
- France
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Infection, Human Immunodeficiency Virus
Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529
The current food effect study is being performed to support a Phase 3 study with BMS 663068. Results from this study will inform whether patients in the upcoming Phase 3 study can be given the flexibility to dose BMS-663068 in…
- Trial name
- NCT02164045
- Testing
- BMS-663068
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Prevention
Microbicide/PrEP Acceptability Among Mothers and Male Partners in Africa
The MTN-041 study is a multi-site exploratory study using focus group discussions (FGDs) and in-depth interviews (IDIs) to identify individual, interpersonal, social and cultural factors that may affect potential uptake of two…
- Trial name
- MAMMA (NCT03648931)
- Testing
- Focus Group Discussion (FGD), In-depth Interview (IDI)
- Where
- 4 sites in Malawi, South Africa and 2 more
- Volunteers
- 232 people
- Sponsor
- Microbicide Trials Network
HIV Infections
Daclizumab to Treat HIV-Infected Patients
This study will examine the safety and effectiveness of daclizumab (also called Zenapax or anti-CD25) in reducing viral replication in patients with HIV infection.
- Trial name
- NCT00080431
- Testing
- Daclizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus (HIV)
An Italian Observation of Antiretroviral Treatment in Participants Taking Darunavir/ Cobicistat Plus Emtricitabine and Tenofovir Alafenamide Fumarate
The purpose of this study is to describe the effectiveness of Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF), measured as virological response at Week 48 as per Food and Drug Administration (FDA) snapshot…
- Trial name
- DIAMANTE (NCT03577470)
- Testing
- D/C/F/TAF Fixed-Dose Combination (FDC)
- Where
- 18 sites in Italy
- Volunteers
- 246 people
- Sponsor
- Janssen-Cilag S.p.A.
Infection, Human Immunodeficiency Virus
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
The purpose of this trial is to assess the antiviral activity and safety of a dolutegravir (DTG) containing regimen in HIV-1 infected, antiretroviral therapy (ART)-experienced adults with current or historical failure on an…
- Trial name
- VIKING-3 (NCT01328041)
- Testing
- dolutegravir
- Where
- 89 sites in United States, Belgium and 5 more
- Volunteers
- 183 people
- Sponsor
- ViiV Healthcare
Sexual Behavior, Dis-inhibition
Information About HIV Transmission and Circumcision on Subsequent Sexual Behavior, and the Demand for Circumcision
The purpose of this study is to measure the behavioral effects of learning information about male circumcision and HIV risk on sexual behavior and the demand for male circumcision.
- Trial name
- NCT01895556
- Testing
- Information, Control
- Volunteers
- 1,200 people
- Sponsor
- Rebecca Thornton
Filarial Infection, HIV Infections
Changes in HIV Viral Load in Patients Undergoing Treatment for Filariasis
This study, sponsored by the National Institutes of Health and the Tuberculosis Research Centre and YRG-Care in Chennai, India, will examine how treatment of lymphatic filariasis in HIV-infected patients influences the amount of…
- Trial name
- NCT00344279
- Where
- 3 sites in India
- Volunteers
- 1,000 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Self Efficacy, HIV Prevention
TAKE Steps: Motivational Interviewing to Prevent STIs
This study will consist of a randomized controlled trial of a motivational interviewing intervention for adolescents with diagnosed sexually transmitted infections (STIs).
- Conditions
- Self Efficacy, HIV Prevention, STI Prevention
- Trial name
- TAKE Steps (NCT05215262)
- Testing
- Treat Act Know Engage (T.A.K.E.) Steps, Standard or Care
- Where
- 5 sites in United States
- Volunteers
- 94 people
- Sponsor
- Children's Hospital of Philadelphia
HIV Infections
Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection
The purpose of this study is to evaluate the safety of the experimental drug Bay 50-4798 in HIV positive patients receiving HAART and to test the drug's effect on the CD4+ T-cell count.
- Trial name
- NCT00059462
- Testing
- Interleukin-2 SA, HAART
- Where
- 11 sites in United States, France and 1 more
- Volunteers
- 56 people
- Sponsor
- Bayer
HIV Infections
Effect of an Intrauterine Contraceptive Device (IUD) in HIV Infected Women
Oral contraceptives (OCs) are not a good option for some HIV infected women because of the potential for drug interactions between OCs and anti-HIV drugs; additionally, OCs may increase the risk of transmitting HIV to sexual…
- Trial name
- NCT00096694
- Testing
- Levonorgestrel-releasing intrauterine device (IUD)
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 41 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients
To compare AS-101 dosing schedules (once a week; 3 times a week; 5 times a week; or 5 times per week on alternate weeks) on the effect on clinical immunology and virus burden in AIDS or AIDS related complex (ARC) patients.
- Trial name
- NCT00002266
- Testing
- AS-101
- Where
- United States
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Maternal and Child Health Outcomes
Vitamins, Breastmilk HIV Shedding, and Child Health
The purpose of this study is to analyze stored samples and data collected during the conduct of the study "A Trial of Vitamins in HIV Progression and Transmission" (HD32257).
- Trial name
- NCT00197756
- Testing
- Vitamin A alone, Multivitamins excluding vitamin A, multivitamins including vitamin A
- Where
- United States
- Volunteers
- 771 people
- Sponsor
- Harvard School of Public Health (HSPH)
HIV Infections, Hepatitis C
Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4
A study concerning viral kinetic with 10 co-infected HIV-HCV patients on treatment with peginterferon alfa-2a + ribavirin o IFN + ribavirin was reported in Conference on Retroviruses and Opportunistic Infections 2002 by Dr.
- Trial name
- NCT00612755
- Testing
- Peginterferon alfa-2a + ribavirin
- Where
- 19 sites in Spain
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Hospital Clinico Universitario San Cecilio
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.